FDA rejects Amgen’s application for biosimilar trastuzumab ABP 980

FDA provides CRL rejecting Amgen’s application for biosimilar trastuzumab ABP 980, filed August 2017.  Amgen states “we do not expect this to impact our US launch plans.”